Translational Haematology
Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy
Search for publications
Only original articles, editorials, guidelines.
-
Lahuerta JJ, San-Miguel JF, Jiménez-Ubieto A, Alonso Fernández R, Paiva B, Puig N, Cedena MT, Gutierrez NC, Calasanz MJ, Fernandez M, Ríos-Tamayo R, Oriol A, Blanchard MJ, Carrillo-Cruz E, Martínez-Martínez R, Bargay J, Sureda A, de la Rubia J, Hernandez Garcia MT, Cabañas V, Casado Montero LF, Palomera Bernal L, Gonzalez-Montes Y, Martínez-López J, Rodriguez-Otero P, Krsnik I, Arguiñano JM, Gonzalez-Garcia ME, Ocio EM, de la Cruz J, Mateos MV, Rosiñol L, Bladé J.
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
Blood . : .
-
Mauro MJ MD, Minami Y, Hochhaus A, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes J, Abdo A, Fogliato LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Chee L, Garcia-Gutierrez V, Sasaki K, Boquimpani C, Kapoor S, Espurz-Abad N, Dhamal V, Rea D.
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.
Blood Advances . : .